Últimas noticias sobre Alzamend Neuro (NASDAQ:ALZN) Bolsa

ALZAMEND NEURO INC

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

Management

Wells Fargo Appoints Charlie Scharf As Chairman

On July 24, 2025, Future FinTech Group Inc. (the "Company") entered into a securities purchase agreement (the "Equity SPA") with certain institutional and individual investors (each, a "Purchaser"), pursuant to which the Company agreed to issue and sell, and the Purchasers agreed to purchase, up to an aggregate of 15,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $2.00 per share. No significant shareholder or officer of the Company participated in the First Transaction. The initial closing is capped at no more than 19.9% of the Company's outstanding Common Stock as of the closing date (the "19.9% Limit") and with the issuance of the remaining shares of Common Stock pursuant to the Equity SPA subject to shareholder approval as explained below.
 &nbsp;

General

FTFT

Future FinTech Group Entered Securities Purchase Agreement With Institutional And Individual Investors Up To 15M Shares At $2/Share

Mercer Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.87) by 48.28 percent. This is a 27.72 percent decrease over losses of $(1.01) per share from the same period last year. The company reported quarterly sales of $453.52 million which missed the analyst consensus estimate of $514.00 million by 11.77 percent. This is a 9.18 percent decrease over sales of $499.38 million the same period last year.

Earnings

Earnings Misses

MERC

Mercer Intl Q2 EPS $(1.29) Misses $(0.87) Estimate, Sales $453.52M Miss $514.00M Estimate

WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.17 by 2.86 percent. This is a 12.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $112.621 million which beat the analyst consensus estimate of $111.370 million by 1.12 percent. This is a 5.22 percent increase over sales of $107.034 million the same period last year.

Earnings Beats

WisdomTree Q2 Adj. EPS $0.18 Beats $0.17 Estimate, Sales $112.621M Beat $111.370M Estimate

Astrotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTC#NASDAQ">ASTC</a>), a provider of next generation security screening and detection technologies based on Mass Spectrometry ("Mass Spec"), today announced the first sale and deployment of its TRACER 1000&#x2122; Narcotics Trace Detector ("TRACER 1000 NTD&#x2122;") in Vietnam, by way of its subsidiary 1st Detect. This milestone marks a significant step in expanding the 1st&nbsp;Detect footprint across Southeast Asia and reinforces its commitment to enhancing narcotics trace detection inspection capabilities in global emerging markets.
"This first NTD system in Vietnam demonstrates Astrotech's growing presence in Asia and the increasing trust commercial and critical infrastructure operators are placing in our advanced technology," said Tom Pickens, CEO of Astrotech Corp. "We are honored to support Vietnam's security modernization efforts with next generation Mass Spec based trace detection and comprehensive library capabilities to deliver the accuracy, breadth and speed needed to counter the global narcotics trade."
"The global narcotics and explosives trace detection market is estimated at more than $7 billion1 and growing rapidly, driven by a strong demand for innovation as law enforcement and public safety agencies combat an ever growing range of drugs and explosives," said Pickens. "1st Detect offers a highly differentiated solution that not only provides the precision and reliability of Mass Spec analysis to clearly and accurately identify a substance, but also a virtually unlimited library capability to support the detection of new concerns and threats as they are identified in this fast-evolving marketplace."
TRACER 1000 NTD&#x2122;, designed for confirmatory trace narcotics detection, enables security authorities to detect threats, contraband, and illicit materials with near-zero false alarm rate. 1st Detect's goal is to ensure that detection is future proof and gives authorities confidence in its results due to the highly precise nature of the Mass Spec technology.

Asset Sales

ASTC

Astrotech Corporation Announces The First Sale And Deployment Of Its Tracer 1000 Narcotics Trace Detector In Vietnam, By Way Of Its Subsidiary 1st Detect

Cryptocurrency trading platform company Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) reported second-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Thursday.</a>
Here are the highlights.
 What Happened: Coinbase reported second-quarter revenue of $1.5 billion, down 26% quarter-over-quarter. The revenue missed a Street consensus estimate of $1.69 billion, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0731"> from Benzinga Pro.</a>
Transaction revenue in the quarter was $764 million, down 39% quarter-over-quarter.
Subscription and services revenue was $656 million, down 6% quarter-over-quarter.
Trading volume was $237 billion in the quarter, down 40% quarter-over-quarter.
Transaction revenue was down year-over-year for both the consumer and institutional segments. The company said crypto spot volume was down 31% globally and 32% in the U.S. year-over-year.
The company ended the second quarter with $9.3 billion in USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) and $1.8 billion in crypto assets, which includes weekly Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) purchases.
Adjusted earnings per share of 12 cents missed the Street consensus estimate of $1.35.
Coinbase said its derivatives trading volume hit all-time highs in the quarter.
The company highlighted its growing USDC adoption, Base Chain going live in more places and scaling, the launch of Base APP in open beta with over 700,000 on the waitlist, and various cryptocurrency legislation pieces, including the GENIUS Act, signed into law.
"These bills provide a clear regulatory foundation for stablecoins and digital assets, potentially unlocking new opportunities for Coinbase and reinforcing U.S. leadership in digital finance," the company said.
Trading volume by cryptocurrency was:
<ul class="wp-block-list">
<li>Bitcoin: 30%</li>
<li>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>): 15%</li>
<li>Other: 55%</li>
</ul>
This compares to the first quarter, where Bitcoin was 27%, Ethereum was 11% and XRP Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) was 11%
Transaction revenue by cryptocurrency was:
<ul class="wp-block-list">
<li>Bitcoin: 34%</li>
<li>Ethereum: 12%</li>
<li>XRP:13%</li>
<li>Other: 41%</li>
</ul>
This compares to the first quarter when Bitcoin was 26%, Ethereum was 10%, Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) was 10% and XRP was 18%.
Read Also: <a href="https://www.benzinga.com/trading-ideas/previews/25/07/46742773/coinbase-q2-preview-can-white-house-momentum-bitcoin-all-time-highs-help">Coinbase Q2 Preview: Can White House Momentum, Bitcoin All-Time Highs Help?</a>
What's Next: Coinbase said it expects July transaction revenue to be $360 million.
The company is guiding for third-quarter subscription and services revenue to be in the range of $665 million to $745 million, surpassing the levels of the second quarter. The growth is attributed to higher cryptocurrency prices and stablecoin revenue.
Coinbase is guiding for higher expenses for the third quarter with higher headcount.
"The opportunities for growth have expanded substantially with increased regulatory clarity. We are taking this opportunity to grow headcount in exciting areas we expect to become meaningful in the future, including international expansion," the company said.
COIN Price Action: Coinbase stock is down 5.8% to $356.04 in after-hours trading Thursday versus a 52-week trading range of $142.58 to $444.64.
 Read Next: 
<ul class="wp-block-list">
<li>&nbsp;<a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46721901/jpmorgan-partners-with-coinbase-to-expand-crypto-access-for-80m-customers" target="_blank" rel="noreferrer noopener">JPMorgan Partners With Coinbase To Expand Crypto Access For 80M Customers</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$USDC

$XRP

COIN

Coinbase Q2 Earnings Highlights: Sales, EPS Miss, 40% Slide In Trading Volume

<a href="https://www.bloomberg.com/news/articles/2025-07-31/trump-asks-bank-ceos-to-pitch-on-fannie-freddie-stock-offerings" title="https://www.bloomberg.com/news/articles/2025-07-31/trump-asks-bank-ceos-to-pitch-on-fannie-freddie-stock-offerings">https://www.bloomberg.com/news/articles/2025-07-31/trump-asks-bank-ceos-to-pitch-on-fannie-freddie-stock-offerings</a>

FMCC

FNMA

'Trump Asks Bank CEOs to Pitch on Fannie, Freddie Stock Offerings' - Bloomberg News

Board Authorizes Purchase of Up to 3 Million Shares of Common Stock

Buybacks

AREN

The Arena Group Authorizes 3M Share Repurchase Program

- Purchases 4.9% of Great Elm Group's Common Stock; $150 Million Debt Investment in Monomoy Properties REIT to Accelerate Industrial Real Estate Platform Expansion –
- Company to Host Conference Call at 8:30 a.m. ET on August 1, 2025 -
Transaction Highlights:
<ul>
<li>Certain funds affiliated with Kennedy Lewis Investment Management LLC ("KLIM") purchase 4.9% of Great Elm Group, Inc's ("GEG") outstanding common stock at market price, approximately $2.11 per share.</li>
<li>$150 million of term loans in total strategic financing for Monomoy Properties REIT, LLC ("Monomoy REIT") from KLIM to catalyze growth across the Monomoy industrial real estate platform recently consolidated under Great Elm Real Estate Ventures, LLC ("Real Estate Ventures")</li>
<li>KLIM appoints board representatives at both GEG and Monomoy REIT, underscoring its commitment to a long-term partnership &nbsp;</li>
</ul>
PALM BEACH GARDENS, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- &nbsp;Great Elm Group, Inc. ("we," "us," "our," "GEG" or "Great Elm,") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEG#NASDAQ">GEG</a>), a publicly traded alternative asset manager, today announced a transformational strategic partnership with KLIM, an institutional alternative investment firm focused on opportunistic credit strategies including real estate with over $30 billion in assets under management. This partnership delivers up to $150 million in leverageable capital to support continued growth across Great Elm's real estate platform, which includes Monomoy REIT, Monomoy CRE (MCRE), Monomoy Construction Services (MCS), and Monomoy BTS (MBTS) (together "Monomoy"). Monomoy offers a full-service suite of project management, procurement, construction management, asset management, market analysis and feasibility services for its industrial real estate tenants.
Under the terms of the transaction, KLIM is providing an initial $100 million term loan to Monomoy REIT, and the option for an additional $50 million in future capital. Additionally, KLIM is purchasing 4.9% of GEG's common stock at market price, approximately $2.11 a share, and will hold an initial 15% profits interest (which may be increased to 20% under certain circumstances) in the newly formed Great Elm Real Estate Ventures, LLC, which consolidates GEG's real estate subsidiaries: MCRE, MCS, and MBTS.

Kennedy Lewis Invests $150M In Monomoy REIT, Acquires 4.9% Stake In Great Elm Group To Accelerate Industrial Real Estate Growth

RKLB

Rocket Lab Opens Window For Its Next Mission For Multi-launch Customer, Institute For Q-shu Pioneers Of Space, Marking Electron's 69th Mission To Date And 11th Launch This Year

MODG

Topgolf Callaway Brands CEO Artie Starrs To Resign

<ul>
<li>Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 &nbsp;</li>
<li>4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 &nbsp;</li>
<li>Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment</li>
</ul>
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio&#xAE; (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies.
"This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey."
With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of &lt;70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6.
The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1.

Biotech

Novartis Announces That The U.S FDA  Has Approved A Label Update For Leqvio Allowing Its Use As Monotherapy Along With Diet And Exercise To Reduce Low-Density Lipoprotein Cholesterol In Adults With Hypercholesterolemia1.

Mirion Acquires Certrec For $81M

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has outperformed the market over the past 5 years by 1.76% on an annualized basis producing an average annual return of 15.63%. Currently, General Motors has a market capitalization of $50.78 billion. 
Buying $100 In GM: If an investor had bought $100 of GM stock 5 years ago, it would be worth $208.03 today based on a price of $53.34 for GM at the time of writing.
<h3>General Motors's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753994716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In General Motors 5 Years Ago Would Be Worth This Much Today

YSXT

YSX TECH. CO. 2025 Total Revenue $71.5M, Up 22%

Natuzzi S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTZ#NYSE">NTZ</a>) ("Natuzzi" or the "Company") announced today that Mr. Antonio Achille, who has served as the Company's Chief Executive Officer and executive director since 2021, stepped down from his roles effective July 30, 2025, to pursue new professional opportunities.
Pending the appointment of a successor, the Board of Directors has temporarily delegated the CEO's powers and responsibilities to the Executive Chairman, Mr. Pasquale Natuzzi, who will serve in an interim capacity.

Natuzzi CEO Antonio Achille Resigns, Effective July 30, 2025; Board Temporarily Delegates CEO's Responsibilities To Executive Chairman, Pasquale Natuzzi

RBOT

Vicarious Surgical Appoints Stephen From As CEO

Azenta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) today announced that it has entered a collaboration with&nbsp;Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason&#xAE; genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicine for patients worldwide.
The MyReason research program is an innovative initiative designed to uncover insights into the genetic mechanisms underlying kidney disease. To date, more than 35,000 participants have been registered in the program and provided biospecimens, with a goal of reaching 50,000 participants over the next two years.
Nephronomics holds exclusive commercial rights to the MyReason dataset, which anchors the Nephronomics Atlas, an unparalleled resource of deep clinical and genomic cardio-kidney-metabolic (CKM) disease data. Nephronomics aims to develop targeted therapies and redefine CKM disease care through precision medicine insights. By leveraging proprietary artificial intelligence (AI)/machine learning (ML) models trained on this comprehensive dataset, Nephronomics identifies novel disease subtypes, protective genetic variants, and therapeutic targets.
Azenta will support the collaboration by delivering genomic sequencing through GENEWIZ and managing long-term sample storage within its global biorepository network. With decades of experience in multiomics analysis and sample management solutions, Azenta is uniquely positioned to provide end-to-end solutions for complex research programs.

AZTA

Azenta Joins Frenova And Nephronomics To Power MyReason Genomics Program Aiming To Transform Precision CKM Disease Care

FBLG

FibroBiologics H1 2025 Net Loss ~$9.6M

BWXT

BWX Technologies Appoints Mike Fitzgerald As CFO

Health Care

Press Releases

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor's Drink Expansion – More Stocks Inside

Financing

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Comments

Alzamend Neuro

Noticias

Últimas noticias sobre Alzamend Neuro (NASDAQ:ALZN) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL